Binder, Lutz

[["dc.bibliographiccitation.issue","19"],["dc.bibliographiccitation.journal","Circulation"],["dc.bibliographiccitation.volume","106"],["dc.contributor.author","Pieske, Burkert M."],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","von Lewinski, Dirk"],["dc.contributor.author","Sander, Josemir W."],["dc.contributor.author","Schenker, W."],["dc.contributor.author","Wiesenthal, T."],["dc.contributor.author","Hess, Georg"],["dc.contributor.author","Binder, L."],["dc.date.accessioned","2018-11-07T09:50:05Z"],["dc.date.available","2018-11-07T09:50:05Z"],["dc.date.issued","2002"],["dc.format.extent","683"],["dc.identifier.isi","000179142703409"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35641"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","American-Heart-Association Abstracts From Scientific Sessions"],["dc.relation.eventlocation","CHICAGO, ILLINOIS"],["dc.relation.issn","0009-7322"],["dc.title","NT-pro brain natriuretic peptide as marker for severity and prognosis of left ventricular dysfunction"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Pieske, Burkert M."],["dc.contributor.author","Binder, L."],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Hruska, N."],["dc.contributor.author","Hess, Georg"],["dc.contributor.author","Konstantinides, Stavros V."],["dc.date.accessioned","2018-11-07T10:13:47Z"],["dc.date.available","2018-11-07T10:13:47Z"],["dc.date.issued","2002"],["dc.format.extent","580"],["dc.identifier.isi","000179753302165"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40501"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","W B Saunders Co Ltd"],["dc.publisher.place","London"],["dc.relation.conference","Congress of the European-Society-of-Cardiology"],["dc.relation.eventlocation","BERLIN, GERMANY"],["dc.relation.issn","0195-668X"],["dc.title","NT-pro brain natriuretic peptide as novel marker for diagnosis and prognosis of acute pulmonary embolism"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e000182"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Open Heart"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Seegers, Joachim"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Grüter, Timo"],["dc.contributor.author","Ammermann, Antje"],["dc.contributor.author","Weber-Krüger, Mark"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Binder, Lutz"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Gröschel, Klaus"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Wachter, Rolf"],["dc.date.accessioned","2017-09-07T11:52:34Z"],["dc.date.available","2017-09-07T11:52:34Z"],["dc.date.issued","2015"],["dc.identifier.doi","10.1136/openhrt-2014-000182"],["dc.identifier.gro","3144967"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13598"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/2650"],["dc.notes.intern","Crossref Import"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","public"],["dc.relation.issn","2053-3624"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Natriuretic peptides for the detection of paroxysmal atrial fibrillation"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Molecular and Cellular Cardiology"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Pieske, Burkert M."],["dc.contributor.author","Binder, L."],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Hruska, N."],["dc.contributor.author","Hess, Georg"],["dc.contributor.author","Konstantinides, Stavros V."],["dc.date.accessioned","2018-11-07T10:28:41Z"],["dc.date.available","2018-11-07T10:28:41Z"],["dc.date.issued","2002"],["dc.format.extent","A50"],["dc.identifier.doi","10.1016/S0022-2828(02)90926-0"],["dc.identifier.isi","000176496800204"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43481"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Academic Press Ltd- Elsevier Science Ltd"],["dc.publisher.place","London"],["dc.relation.issn","1095-8584"],["dc.relation.issn","0022-2828"],["dc.title","NT-proBNP as novel marker for diagnosis and severity of acute pulmonary embolism"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Kockskaemper, Anke"],["dc.contributor.author","Post, Heiner"],["dc.contributor.author","Kleta, Sibylle"],["dc.contributor.author","Wachter, R. Rolf"],["dc.contributor.author","Binder, L."],["dc.contributor.author","Pieske, Burkert M."],["dc.date.accessioned","2018-11-07T11:24:44Z"],["dc.date.available","2018-11-07T11:24:44Z"],["dc.date.issued","2009"],["dc.format.extent","170"],["dc.identifier.isi","000208702602083"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56472"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.issn","0195-668X"],["dc.title","Echocardiographic diagnosis of diastolic dysfunction: E/e is superior to complex algorithms in predicting a clinical impairment in exercise capacity"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","14"],["dc.bibliographiccitation.journal","BMC Family Practice"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Koschack, Janka"],["dc.contributor.author","Scherer, Martin"],["dc.contributor.author","Luers, Claus"],["dc.contributor.author","Kochen, Michael M."],["dc.contributor.author","Wetzel, Dirk"],["dc.contributor.author","Kleta, Sibylle"],["dc.contributor.author","Pouwels, Claudia"],["dc.contributor.author","Wachter, R. Rolf"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Pieske, Burkert M."],["dc.contributor.author","Binder, Lutz"],["dc.date.accessioned","2018-11-07T11:18:13Z"],["dc.date.available","2018-11-07T11:18:13Z"],["dc.date.issued","2008"],["dc.description.abstract","Background: Screening of primary care patients at risk for left ventricular systolic dysfunction by a simple blood-test might reduce referral rates for echocardiography. Whether or not natriuretic peptide testing is a useful and cost-effective diagnostic instrument in primary care settings, however, is still a matter of debate. Methods: N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, clinical information, and echocardiographic data of left ventricular systolic function were collected in 542 family practice patients with at least one cardiovascular risk factor. We determined the diagnostic power of the NT-proBNP assessment in ruling out left ventricular systolic dysfunction and compared it to a risk score derived from a logistic regression model of easily acquired clinical information. Results: 23 of 542 patients showed left ventricular systolic dysfunction. Both NT-proBNP and the clinical risk score consisting of dyspnea at exertion and ankle swelling, coronary artery disease and diuretic treatment showed excellent diagnostic power for ruling out left ventricular systolic dysfunction. AUC of NT-proBNP was 0.83 (95% CI, 0.75 to 0.92) with a sensitivity of 0.91 (95% CI, 0.71 to 0.98) and a specificity of 0.46 (95% CI, 0.41 to 0.50). AUC of the clinical risk score was 0.85 (95% CI, 0.79 to 0.91) with a sensitivity of 0.91 (95% CI, 0.71 to 0.98) and a specificity of 0.64 (95% CI, 0.59 to 0.67). 148 misclassifications using NT-proBNP and 55 using the clinical risk score revealed a significant difference (McNemar test; p < 0.001) that was based on the higher specificity of the clinical risk score. Conclusion: The evaluation of clinical information is at least as effective as NT-proBNP testing in ruling out left ventricular systolic dysfunction in family practice patients at risk. If these results are confirmed in larger cohorts and in different samples, family physicians should be encouraged to rely on the diagnostic power of the clinical information from their patients."],["dc.identifier.doi","10.1186/1471-2296-9-14"],["dc.identifier.isi","000254051900001"],["dc.identifier.pmid","18298821"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8928"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54989"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1471-2296"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Lueers, Claus"],["dc.contributor.author","Kleta, Sibylle"],["dc.contributor.author","Wachter, R. Rolf"],["dc.contributor.author","Pouwels, Claudia"],["dc.contributor.author","Binder, L."],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Kochen, Michael M."],["dc.contributor.author","Pieske, Burkert M."],["dc.date.accessioned","2018-11-07T10:56:07Z"],["dc.date.available","2018-11-07T10:56:07Z"],["dc.date.issued","2005"],["dc.format.extent","742"],["dc.identifier.isi","000233987105318"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49938"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","27th Congress of the European-Society-of-Cardiology"],["dc.relation.eventlocation","Stockholm, SWEDEN"],["dc.relation.issn","1522-9645"],["dc.relation.issn","0195-668X"],["dc.title","Impact of NTproBNP and NTproANP for the diagnosis of diastolic or systolic dysfunction."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Pieske, Burkert M."],["dc.contributor.author","von Lewinski, Dirk"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Sander, Josemir W."],["dc.contributor.author","Schenker, W."],["dc.contributor.author","Yksel, T."],["dc.contributor.author","Hess, Georg"],["dc.contributor.author","Binder, L."],["dc.date.accessioned","2018-11-07T10:13:42Z"],["dc.date.available","2018-11-07T10:13:42Z"],["dc.date.issued","2002"],["dc.format.extent","575"],["dc.identifier.isi","000179753302147"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40488"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","W B Saunders Co Ltd"],["dc.publisher.place","London"],["dc.relation.conference","Congress of the European-Society-of-Cardiology"],["dc.relation.eventlocation","BERLIN, GERMANY"],["dc.relation.issn","0195-668X"],["dc.title","NT-pro Brain natriuretic peptide as marker for severity and prognosis of left ventricular dysfunction"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie"],["dc.bibliographiccitation.volume","55"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Kochen, Michael M."],["dc.contributor.author","Rautenstrauch, N."],["dc.contributor.author","Binder, L."],["dc.contributor.author","Luers, Claus"],["dc.contributor.author","Wetzel, D."],["dc.contributor.author","Pieske, Burkert M."],["dc.date.accessioned","2018-11-07T08:30:41Z"],["dc.date.available","2018-11-07T08:30:41Z"],["dc.date.issued","2005"],["dc.format.extent","133"],["dc.identifier.isi","000227116800155"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16947"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.issn","0937-2032"],["dc.title","Relations between bonding style, Type D personality and psychosomatic conditions in patients with cardiovascular risk factors - Psychometric findings from the MedViP study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","874"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","882"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Schmidt, Albrecht G."],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Binder, Lutz"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Pieske, Burkert"],["dc.date.accessioned","2017-09-07T11:45:19Z"],["dc.date.available","2017-09-07T11:45:19Z"],["dc.date.issued","2010"],["dc.description.abstract","Aims Increasing evidence suggests that enhanced aldosterone signalling plays a key role in the onset and progression of diastolic heart failure (DHF). Aldo-DHF will test the hypothesis that aldosterone receptor blockade by spironolactone will improve exercise capacity and diastolic function in patients with DHF. Methods Aldo-DHF is a randomized, placebo-controlled, double-blinded, two-armed, multicentre, parallel group study. Four hundred and twenty patients with DHF will be randomly assigned to receive spironolactone 25 mg per day or placebo. The main inclusion criteria are: age >= 50 years, New York Heart Association preserved left ventricular ejection fraction (>= 50%), and echocardiographic evidence of diastolic dysfunction. The two primary endpoints are changes in exercise capacity (peak VO(2), spiroergometry) and in diastolic function (E/e, echocardiography) after 12 months. Secondary endpoints include effects of spironolactone on additional parameters of exercise performance and diastolic as well as systolic function, neurohumoral activation, and quality of life. Morbidity and mortality as well as safety aspects will also be assessed. Conclusion Aldo-DHF is the first large-scale clinical trial to evaluate the effects of aldosterone receptor blockade on exercise capacity and diastolic function in patients with DHF. Aldo-DHF will provide important information about the clinical course of this condition and may have significant impact on treatment strategies and future trials in these patients."],["dc.identifier.doi","10.1093/eurjhf/hfq087"],["dc.identifier.gro","3142879"],["dc.identifier.isi","000281200100017"],["dc.identifier.pmid","20538867"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/331"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","1388-9842"],["dc.title","Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]